Zhenluo Science and Saihe Medical Honored in 2024 Digital Health 'New Quality Productivity' Innovation List
SONOSEMI
Active Vascular Implantable and Interventional Medical Device R&D and Manufacturer
Recently,Authoritative medical information platform Vbdata released the selection results of 2024 Digital Health New Quality Productivity Innovation Cases,GYENNO Technologies Co., Ltd. and Sonosemi Medical Co., Ltd., portfolio companies of Sequoia Capital China, have been successfully selected.Releasing the value of digital health, innovating application scenarios in the healthcare industry, accelerating the R&D of new digital health technologies and products, and empowering the upgrading and development of new productivity in the healthcare industry are important engines for reshaping the industry through new drivers and evolutionary innovation in this new stage and context. To this end, VB100 of Vbdata.cn is launching the 2024 Digital Health New Productivity Innovation Development Case Selection Activity, aiming to showcase the innovative achievements and results of the selected cases in specific application fields and provide a precise display platform for the selected cases.
Case Name:Construction of a New Generation Parkinson's Disease Intelligent Specialty Center
Selected Units:Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Collaborating Units:GYENNO Technologies Co., Ltd.
Application Segmentation/Department/Disease:Neuroscience, Parkinson's Disease
Annual Innovation Achievements and Results:In April 2020, the first one-stop diagnosis and treatment center for Parkinson's disease in China was established at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. Ruijin Hospital and GYENNO Technologies Co., Ltd. jointly built a model of the "New Generation Intelligent Specialty Center for Parkinson's Disease" and its application demonstration. By combining classic diagnostic and treatment technologies with new artificial intelligence and digital technologies, the "New Generation Intelligent Specialty Center for Parkinson's Disease" has implemented intelligent medical processes such as pre-consultation within the hospital, testing and examination, intelligent symptom assessment, and visual consultation, as well as intelligent management models outside the hospital including continuous quantitative monitoring, regular quantitative evaluation, effective doctor-patient interaction, and dynamic efficacy optimization. For the first time globally, this has realized the comprehensive diagnosis and treatment system and model for Parkinson’s disease across all time and space, truly achieving the broad-sense one-stop diagnosis and treatment of "all time, all space, and the entire course of the disease," namely the "New Generation Intelligent Specialty Center for Parkinson's Disease." Based on the application demonstration and related innovative technologies, the teams from Ruijin Hospital and GYENNO Technologies have published a series of high-quality papers in internationally high-impact journals (including several top publications in the field), forming substantial clinical evidence. They are further conducting prospective multi-center clinical studies in collaboration with multiple top hospitals across China. Currently, the related concepts have empowered more than 90% of the Parkinson's disease specialty centers in China.
GYENNO Technologies Co., Ltd. is a global leading innovative medical technology and service company in the field of central nervous system diseases. GYENNO Technologies collaborates deeply with global universities and experts on the research and clinical application of innovative medical devices, clinical data platforms, and chronic disease management service systems for Parkinson's disease, establishing comprehensive solutions covering diagnosis, evaluation, treatment, rehabilitation, and personalized management. To date, the company’s software and hardware systems have empowered over 90% of China's top Parkinson's disease centers, and 40% of global original drug enterprises are working with GYENNO Technologies to explore real-world evidence and achieve new commercial drivers.
Case Name:Intracardiac Ultrasound Imaging System
Selected Units:Sonosemi Medical Co., Ltd.
Application Segmentation/Department/Disease:Cardiovascular
Annual Innovation Achievements and Results:Intracardiac Echocardiography (ICE) technology ingeniously combines phased-array ultrasound imaging with cardiac catheterization, providing an innovative ultrasound imaging solution for percutaneous vascular interventional procedures. SONOSEMI's ICE system consists of the DynaSight® single-use intracardiac echocardiography catheter and the UDG3900 series portable ultrasound diagnostic device. Through a miniature phased-array transducer that continuously emits and receives ultrasound signals, the system achieves real-time, high-quality imaging of intracardiac anatomical structures, becoming an essential imaging tool in cardiac interventional therapy.
SONOSEMI's Self-Developed China-Made ICE System Gains High Recognition from Experts in the DISTINCT Clinical Trial
SONOSEMI is an innovative enterprise specializing in high-end pan-vascular interventional medical devices. Adhering to an integrated business logic of research, production, and sales, along with an open industrial collaboration strategy, the company focuses on product deployment for clinical application scenarios such as coronary artery disease, peripheral vascular disease, and structural heart disease. Its aim is to provide the cardiovascular disease diagnosis and treatment industry with a series of precise and intelligent product solutions.
